TC-L200S(TC-L200S) - 在研适应症：爱泼斯坦-巴尔病毒相关鼻咽癌，鼻咽癌，结外NK-T细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

TCR-T细胞疗法

别名

EBV-specific TCR-T cell with cytokine auto-secreting element (TCRCure Biopharma)、L200、L201/202/203

+ [1]

靶点-

作用方式-

作用机制-

治疗领域

肿瘤口颌疾病耳鼻咽喉疾病+ [3]

在研适应症

爱泼斯坦-巴尔病毒相关鼻咽癌鼻咽癌结外NK-T细胞淋巴瘤

非在研适应症-

原研机构

广东天科雅生物医药科技有限公司

在研机构

广东天科雅生物医药科技有限公司

北京天科雅生物科技有限公司

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

1

项与 TC-L200S 相关的临床试验

NCT04509726

/ Completed临床1/2期IIT

Single-Arm Trial of EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Head and Neck Carcinoma Metastatic/Refractory Nasopharyngeal Carcinoma

Epstein-Barr virus (EBV) infections is known to be a high-risk factor to induce cervical cancers. To date, EBV-related nasopharyngeal carcinoma (NPC) is still a major concern in east Asia, especially in China. Concurrent therapies for NPC have limited response rate and high chance of relapse. However, EBV-induced cancers provided an ideal target for T cell-based immunotherapy due to the non-self origins. Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented EBV-epitope become a viable approach to treat this type of cancer. Though engineered T therapies have been well-recognized in hematological cancers, solid cancer treatment has been a major hurdle due to the immune-suppressive tumor microenvironment. Cytokine seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive immunities. therefore, TCR-T cells armed with a cytokine -secretion element could further enhance the efficacy of TCR-T in solid cancers.

开始日期2023-03-01

申办/合作机构

新桥医院

[+1]

100 项与 TC-L200S 相关的临床结果

登录后查看更多信息

100 项与 TC-L200S 相关的转化医学

登录后查看更多信息

100 项与 TC-L200S 相关的专利（医药）

登录后查看更多信息

7

项与 TC-L200S 相关的文献（医药）

2025-12-01·EUROPEAN JOURNAL OF ANAESTHESIOLOGY

The effect of combining lidocaine and ropivacaine on the duration and onset time of an ultrasound-guided infraclavicular brachial plexus nerve block

Article

作者: Yousef, Sina ; Lange, Kai Henrik Wiborg ; Bahuet, Aurelien-Xuan Rosendal ; Knudsen, Rasmus Linnebjerg ; Andersen, Michelle Fog ; Steensbæk, Mathias Therkel ; Harwood, Cecilie Dupont ; Rosenstock, Charlotte Vallentin ; Lundstrøm, Lars Hyldborg ; Nørskov, Anders Kehlet ; Rothe, Christian

BACKGROUND:

The combination of short- and long-acting local anaesthetics is traditionally associated with reduced block duration, though evidence remains inconsistent.

OBJECTIVES:

To investigate the effects of a fixed or reduced dose of a long-acting local anaesthetic (ropivacaine) mixed with a short-acting agent (lidocaine–epinephrine) on duration of analgesia and sensory onset time in lateral infraclavicular blocks.

DESIGN:

Randomised, blinded, active-controlled superiority trial.

SETTING:

A tertiary hospital in the Capital Region of Denmark, from 18 April to 23 November 2024.

PATIENTS:

Seventy-eight patients undergoing hand surgery under lateral infraclavicular brachial plexus nerve block.

INTERVENTION:

Patients were allocated to three groups: R150: 30 ml ropivacaine 5 mg ml −1 , R100–L200: 20 ml ropivacaine 5 mg ml −1 + 10 ml lidocaine–epinephrine 20 mg ml −1 + 5 μg ml −1 and R150-L200: 20 ml ropivacaine 7.5 mg ml −1 + 10 ml lidocaine–epinephrine 20 mg ml −1 + 5 μg ml −1 .

MAIN OUTCOME MEASURES:

The primary outcome was duration of analgesia, and secondary outcomes included sensory onset time.

RESULTS:

The duration of analgesia was 847 (152) min in the R150 group, 536 (198) min in the R100–L200 group, and 671 (234) min in the R150–L200 group. Compared with that in the R150 group, the mean duration of analgesia was reduced by 311 min (95% confidence interval [CI], 212 to 411; P < 0.001) in the R100–L200 group and by 177 min (95% CI, 64 to 289; P = 0.003) in the R150–L200 group. The difference between the R100–L200 and R150–L200 groups was not statistically significant after adjustment for multiple testing (135 min; 95% CI, 13 to 257; P = 0.031). Sensory onset times ranged insignificantly from 17 to 18 min across groups.

CONCLUSION:

Mixing lidocaine–epinephrine with ropivacaine significantly shortened the duration of analgesia by up to 5 h without affecting the sensory onset time. This effect was independent of the ropivacaine dose.

TRIAL REGISTRATION NUMBER:

ClinicalTrials.gov identifier: NCT06381622.

2018-01-01·Journal of dental anesthesia and pain medicine

Comparative evaluation of the efficacy, safety, and hemostatic effect of 2% lidocaine with various concentrations of epinephrine

Article

作者: Karm, Myong-Hwan ; Seo, Kwang-Suk ; Kim, Minyoung ; Park, Fiona D. ; Kim, Hyun Jeong

BACKGROUND:

We evaluated the changes in mean arterial pressure (MAP) and heart rate (HR), and the anesthetic and hemostatic effects, after injection of 2% lidocaine containing various concentrations of epinephrine in rats and mice to determine the appropriate concentration of epinephrine in various anesthetic mixtures.

METHODS:

Rats and mice were randomly allocated to experimental groups: 2% lidocaine without epinephrine (L0), 2% lidocaine with epinephrine 1:200,000 (L200), 1:100,000 (L100), and 1:80,000 (L80). Changes in MAP and HR after administration of the anesthetic mixture were evaluated using a physiological recording system in rats. Onset and duration of local anesthesia was evaluated by pricking the hind paw of mice. A spectrophotometric hemoglobin assay was used to quantify the hemostatic effect.

RESULTS:

MAP increased in response to epinephrine in a dose-dependent manner; it was significantly higher in the L80 group than in the L0 group at 5 min post-administration. The HR was relatively lower in the L0 group than in the L80 group. The time required for onset of action was < 1 min in all evaluation groups. The duration of action and hemostatic effect of the local anesthetic were significantly better in the L200, L100, and L80 groups than in the L0 group.

CONCLUSION:

L200 demonstrated relatively stable MAP and HR values with satisfactory efficacy and hemostatic effect. L200 might be a better local anesthetic for dental patients in terms of anesthetic efficacy and safety.

2015-01-01·Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

[Leptin promotes the proliferation of airway smooth muscle cells and the expressions of HIF-1α and NF-κB of hypoxic rats].

Article

作者: Chen, Xianfeng ; Chen, Lin ; Shi, Ruirui ; Zhu, Shuyang ; Zhu, Jiechen

OBJECTIVE:

To investigate the effect of leptin on the proliferation of airway smooth muscle cells (ASMCs) and the expressions of hypoxia-inducible factor-1α (HIF-1α) and nuclear factor-kappa B (NF-κB) of hypoxic rats.

METHODS:

The rat ASMCs were cultured under normoxic and hypoxic states. The hypoxic cells were divided into hypoxia group, leptin 50 μg/L hypoxia group (L50 group), leptin 100 μg/L hypoxia group (L100 group), leptin 200 μg/L hypoxia group (L200 group), leptin 200 μg/L and leptin receptor antibody hypoxia group (ob-R antibody group) by random number table. All the groups are cultured for 24 hours. Then the CCK-8 method was used to assay cell proliferation rate, and Western blotting and real-time RT-PCR to measure the expressions of HIF-1α and NF-κB at protein and mRNA levels.

RESULTS:

Compared with the normoxic group, each hypoxia group had significantly increased cell proliferation . Compared with the hypoxia group, cell proliferation rate was significantly raised in L50, L100 and L200 groups, and it was positively correlated with the concentration (r=0.992). Compared with L50, L100 and L200 groups, the ob-R antibody group showed significantly decreased cell proliferation rate. Compared with the normoxic group, each hypoxic group has increased expressions of HIF-1α and NF-κB mRNA and proteins; compared with the hypoxia group, the expressions were significantly elevated in the L50, L100 and L200 groups and showed a positive correlation with the concentration; but the expressions were reduced in the ob-R antibody group as compared with L50, L100 and L200 groups.

CONCLUSION:

Leptin can promote rat ASMCs proliferation and the expressions of HIF-1α and NF-κB under hypoxic condition.

100 项与 TC-L200S 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
爱泼斯坦-巴尔病毒相关鼻咽癌	临床2期	中国	北京天科雅生物科技有限公司	2023-03-01
鼻咽癌	临床2期	中国	广东天科雅生物医药科技有限公司	2023-03-01
结外NK-T细胞淋巴瘤	临床1期	中国	广东天科雅生物医药科技有限公司	-